Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery

Journal of the American College of Cardiology

Volumn 51, Issue 20, 2008, Pages 1938-1943

  Shah, Sanjiv J ^a,b   Waters, David D ^a   Barter, Philip ^c   Kastelein, John J P ^d   Shepherd, James ^e   Wenger, Nanette K ^f   DeMicco, David A ^g   Breazna, Andrei ^g   LaRosa, John C ^h  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HEART RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g PFIZER INC   (United States)

^h STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ARREST; HEART DEATH; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SIDE EFFECT; STROKE; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FEMALE; GRAFT OCCLUSION, VASCULAR; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 43049163859     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.12.054     Document Type: Article

References (15)

1. Charlson M.E., and Isom O.W. Clinical practice. Care after coronary-artery bypass surgery. N Engl J Med 348 (2003) 1456-1463
2. Morwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
3. Domanski M.J., Borkowf C.B., Campeau L., et al. Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators. J Am Coll Cardiol 36 (2000) 1877-1883
4. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid-lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
5. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
6. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
7. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., and Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 (1987) 3233-3240
8. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336 (1997) 153-162
9. Knatterud G.L., Rosenberg Y., Campeau L., et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 102 (2000) 157-165
10. Flaker G.C., Warnica J.W., Sacks F.M., et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol 34 (1999) 106-112
11. Waters D.D., Guyton J.R., Herrington D.M., McGowan M.P., Wenger N.K., and Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 93 (2004) 154-158
12. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
13. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
14. Newman C., Tsai J., Szarek M., Luo D., and Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97 (2006) 61-67
15. Amarenco P., Bogousslavsky J., Callahan III A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559